Longitude Capital, a private investment firm focused on venture growth investments in biotechnology and medical technology, promoted Josh Richardson, M.D. to Managing Director.
Dr. Richardson focuses on investments in biotechnology companies.
He is a board observer at InfaCare Pharmaceutical Corporation, and has played important roles in Longitude’s investments in Aimmune Therapeutics, Akebia Therapeutics, Cadence Pharmaceuticals (acquired by Mallinckrodt), Collegium Pharmaceutical, and Precision Dermatology (acquired by Valeant Pharmaceuticals).
Dr. Richardson originally joined Longitude Capital in 2011 from McKinsey & Company where he was an Engagement Manager. From 2014 to early 2016, Dr. Richardson was a Public Equities Analyst at HealthCor Management where he managed small and mid-cap biotechnology investments.
In 2016, Dr. Richardson re-joined Longitude Capital.
Longitude Capital also added several Vice Presidents to the investment staff in 2016.
– Maxwell Bikoff focuses on investments in medical technology and joins the firm from Cardinal Health, where he held a series of strategy, finance, and operating roles and was most recently the Director of North America Marketing for the Cordis cardiovascular franchise.
– Christina Ghenoiu, Ph.D. focuses on investments in biotechnology and was previously in Biotechnology Equity Research at Cowen and Company, where she covered large and small/mid-cap biotechnology companies.
– Allyson Rinderle focuses on biotechnology investments and previously worked at Aisling Capital and in J.P. Morgan’s Healthcare Investment Banking practice.
– Michael Wert, who worked at Longitude Capital from 2008 to 2012, re-joins the firm’s medical technology practice from Warburg Pincus.
All four operate out of the firm’s Menlo Park, California office.
Led by Managing Director and co-Founder Patrick Enright, Longitude Capital makes venture growth investments in biotechnology and medical technology companies that seek to improve clinical outcomes, enhance quality of life and/or reduce system costs. The firm invests in both privately held and publicly traded life science companies through a variety of investment approaches.
Since 2006, Longitude Capital has raised over $1.2 billion across three funds and has offices in Menlo Park, CA and Greenwich, CT.